Abstract

The utilization of genetically engineered mouse (GEIVI) strains is an integral component of this GTBT P01 program project. The mouse model Core will provide all the necessary expertise, reagents and services for the analysis of exosomal biology with regards to therapeutic applications in GEM models of GBM. The services and reagents provided by this Core will synergize with the individual Projects on the validation and assessment of exosomal-associated molecular biomarkers and the application of cutting edge monitoring technologies for tumor response to therapeutic agents. In addition, the Core will produce and characterize three new GBM GEM strains over the funding period. As such, the Core will support all aspects of the construction of these new transgenic mouse models, including advice, service, technologies and reagents for the optimal design and construction of each specific strain. Using these new strains, the Core will also evaluate and implement new technologies for the detection and monitoring of various exosomal metrics in close relationship with the individual Projects.

Public Health Relevance

The goal of this Core is to provide technical and intellectual support for the use of genetically engineered mouse models of GBM as a conduit for monitoring tumor growth response in relation to therapeutic intervention using exosome-based detection and content analysis

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA069246-16
Application #
8475592
Study Section
Special Emphasis Panel (ZCA1-GRB-P)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
16
Fiscal Year
2013
Total Cost
$230,654
Indirect Cost
$54,207

  Institution

Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199

  Publications

Speranza, Maria-Carmela; Passaro, Carmela; Ricklefs, Franz et al. (2018) Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol 20:225-235
Boussiotis, Vassiliki A; Charest, Alain (2018) Immunotherapies for malignant glioma. Oncogene 37:1121-1141
Sahin, Ayguen; Sanchez, Carlos; Bullain, Szofia et al. (2018) Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. PLoS One 13:e0199414
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Shao, Huilin; Im, Hyungsoon; Castro, Cesar M et al. (2018) New Technologies for Analysis of Extracellular Vesicles. Chem Rev 118:1917-1950
Ricklefs, Franz L; Alayo, Quazim; Krenzlin, Harald et al. (2018) Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv 4:eaar2766
Park, Jongmin; Im, Hyungsoon; Hong, Seonki et al. (2018) Analyses of Intravesicular Exosomal Proteins Using a Nano-Plasmonic System. ACS Photonics 5:487-494
Antoury, Layal; Hu, Ningyan; Balaj, Leonora et al. (2018) Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. Nat Commun 9:3906
Zhou, Shuang; Appleman, Vicky A; Rose, Christopher M et al. (2018) Chronic platelet-derived growth factor receptor signaling exerts control over initiation of protein translation in glioma. Life Sci Alliance 1:e201800029
Min, Jouha; Nothing, Maria; Coble, Ben et al. (2018) Integrated Biosensor for Rapid and Point-of-Care Sepsis Diagnosis. ACS Nano 12:3378-3384

Showing the most recent 10 out of 223 publications